ArticleInternational journal of nanomedicine2019
Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles-Adjuvanted
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer.Molecular biotechnology · 2026Review
- Profile ofHuman vaccines & immunotherapeutics · 2025Article
- Chitosan-based formulations for therapeutic applications. A recent overview.Journal of biomedical science · 2025Review
- mRNA Galsomes Vaccine Protects Budgerigars Against VirulentVaccines · 2025Article
- Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.NPJ vaccines · 2025Article
- Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.Human vaccines & immunotherapeutics · 2024Article
- Review of Intranasal Active Pharmaceutical Ingredient Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Chitosan Nanoparticles for Intranasal Drug Delivery.Pharmaceutics · 2024Review
- Review
- Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine.Carbohydrate polymers · 2022Review
- Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis.Advanced healthcare materials · 2022Article
- Lactobacillus Modulates Chlamydia Infectivity and Genital Tract PathologyFrontiers in microbiology · 2022Article
- Functionalized Nanomaterials as Tailored Theranostic Agents in Brain Imaging.Nanomaterials (Basel, Switzerland) · 2021Review
- Review
- State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections.Journal of nanobiotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsIn this study, we developed a novel immunization strategy, simultaneous (SIM) intramuscular (IM) and intranasal (IN) administration of a
resultsCNPs-Ags with zeta-potential values of 13.12 mV and of 276.1 nm showed excellent stability and optimal size for crossing the mucosal barrier with high 71.7% encapsulation efficiency. SIM-CPN-Ags mediated stronger humoral and mucosal responses by producing meaningfully high levels of IgG and secretory IgA (sIgA) antibodies. The SIM route also led to Ags-specific T-cell responses and increased IFN-γ, IL-2, TNF-α and IL-17A in the splenocyte supernatants. Following respiratory infection with
conclusionSIM immunization with CNPs-adjuvanted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.